Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

University of Miami

Status and phase: Completed; Phase 3

Conditions: Total Hip Replacement; Total Knee Replacement

Treatments: Drug: IV meloxicam; Drug: Ketorolac

Study type: Interventional

Funder types: Other

Identifiers

NCT05291598

20211214

Details and patient eligibility

About

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Enrollment: 223 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients over the age of 18,
2. Patients undergoing primary total knee or primary total hip replacement at the University of Miami Hospital,
3. Patients that have capacity to provide medical consent

Exclusion criteria

1. All patients under the age of 18
2. Prisoners, diabetics, increased risk of bleeding, and pregnant women.
3. Patients with prior surgery or history of infection on the joint of interest.
4. Patients with an estimated glomerular filtration rate (eGFR) <50 ml/min
5. Patients on dialysis or renal transplant.
6. Patients on steroid preoperatively.
7. Allergy to sulfas
8. Inability to provide medical consent.
9. Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements will exclude the participant.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

223 participants in 2 patient groups

Ketorolac group

Active Comparator group

Description:

Participants will receive the institution specific joint replacement pain protocol, including ketorolac.

Treatment:

Drug: Ketorolac

IV meloxicam group

Experimental group

Description:

Participants will receive the institution specific joint replacement pain protocol, however with IV meloxicam substituted for ketorolac.

Treatment:

Drug: IV meloxicam